{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Binks MJ"],"funding":["National Health and Medical Research Council"],"pagination":["13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6305569"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Background</h4>Indigenous children in Australia's Northern Territory are densely colonised with the pneumococcus within weeks of birth antecedent to a high prevalence of acute lower respiratory infection (ALRI). We assessed the impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in pregnancy against infant ALRI in this setting.<h4>Methods</h4>In an open label, allocation concealed, outcome-assessor blinded, randomised controlled trial conducted in the Northern Territory of Australia, healthy Indigenous women aged 17-39 years were randomised to receive the 23vPPV during pregnancy (<i>n</i> = 75; 30-36 weeks gestation), at birth (<i>n</i> = 75), or at 7 months post-partum (<i>n</i> = 77). Randomisation was stratified by community of residence. In a secondary analysis, we"],"journal":["Pneumonia (Nathan Qld.)"],"pubmed_title":["Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia."],"pmcid":["PMC6305569"],"funding_grant_id":["1017225","350499 &amp; 490320"],"pubmed_authors":["Mulholland K","Nelson J","Binks MJ","Leach AJ","Hare KM","Andrews RM","Wilson C","Morris PS","Nelson S","Moberley SA","Balloch A","Torzillo PJ","Carapetis JR","Ware RS","Tang MLK"],"additional_accession":[]},"is_claimable":false,"name":"Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia.","description":"<h4>Background</h4>Indigenous children in Australia's Northern Territory are densely colonised with the pneumococcus within weeks of birth antecedent to a high prevalence of acute lower respiratory infection (ALRI). We assessed the impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in pregnancy against infant ALRI in this setting.<h4>Methods</h4>In an open label, allocation concealed, outcome-assessor blinded, randomised controlled trial conducted in the Northern Territory of Australia, healthy Indigenous women aged 17-39 years were randomised to receive the 23vPPV during pregnancy (<i>n</i> = 75; 30-36 weeks gestation), at birth (<i>n</i> = 75), or at 7 months post-partum (<i>n</i> = 77). Randomisation was stratified by community of residence. In a secondary analysis, we","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2026-05-06T01:02:56.284Z","creation":"2019-03-26T22:33:43Z"},"accession":"S-EPMC6305569","cross_references":{"pubmed":["30603376"],"doi":["10.1186/s41479-018-0057-2"]}}